Advertisement
Advertisement
April 25, 2024
VVT Medical’s ScleroSafe Approved in South Korea for Varicose Vein Treatment
April 25, 2024—V.V.T. Med Ltd. (VVT Medical) announced that the company’s ScleroSafe platform was approved by the Ministry of Food and Drug Safety in South Korea. According to the company, ScleroSafe offers a nonthermal, painless, and anesthesia-free option for minimally invasive treatment of varicose veins.
Additionally, VVT Medical announced completion of the GMP (Good Manufacturing Processes) certification and registration for the therapy.
VVT Medical is an Israel-based developer of products for minimally invasive nonthermal, nontumescent (NT-NT) procedures with both medical and aesthetic indications.
According to the company, the launch of ScleroSafe in Korea signifies a significant stride in VVT Medical’s global expansion strategy. The device has received CE Mark approval and is available in multiple regions, including Europe, Australia, Southeast Asia, and South America.
In September 2023, the company announced FDA 510(k) clearance of ScleroSafe for NT-NT treatment and management of varicosities in superficial veins. This was followed by VVT Medical’s announcement of a strategic distribution agreement with Methapharm Inc. for the marketing of the ScleroSafe platform in the United States.
Advertisement
Advertisement
